Gut microbiome and liver disease

Translational Research

Volumn 179, Issue , 2017, Pages 49-59

  Betrapally, Naga S ^a   Gillevet, Patrick M ^a   Bajaj, Jasmohan S ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER DISEASE; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; HUMAN; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; LIVER DISEASES; MICROBIOLOGY; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER DISEASES;

EID: 84994254086     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.07.005     Document Type: Review

References (131)

1. 1 Machado, M.V., Cortez-Pinto, H., Diet, microbiota, obesity, and NAFLD: a dangerous quartet. Int J Mol Sci, 17, 2016, 481.
2. 2 Bays, H., Adiposopathy, “sick fat,” Ockham's razor, and resolution of the obesity paradox. Curr Atheroscler Rep, 16, 2014, 409.
3. 3 Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
4. 4 Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.-K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
5. 5 Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
6. 6 Vassallo, G., Mirijello, A., Ferrulli, A., et al. Review article: alcohol and gut microbiota–the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther 41 (2015), 917–927.
7. 7 Chiang, D.J., McCullough, A.J., The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis 18 (2014), 157–163.
8. 8 Naveau, S., Giraud, V., Borotto, E., Aubert, A., Capron, F., Chaput, J.C., Excess weight risk factor for alcoholic liver disease. Hepatol Baltim Md 25 (1997), 108–111.
9. 9 Iturriaga, H., Bunout, D., Hirsch, S., Ugarte, G., Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 47 (1988), 235–238.
10. 10 Anthony, P.P., Ishak, K.G., Nayak, N.C., Poulsen, H.E., Scheuer, P.J., Sobin, L.H., The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 31 (1978), 395–414.
11. 11 Garcia-Tsao, G., Wiest, R., Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 18 (2004), 353–372.
12. 12 Neish, A.S., Microbes in gastrointestinal health and disease. Gastroenterology 136 (2009), 65–80.
13. 13 McFall-Ngai, M., Adaptive immunity: care for the community. Nature, 445, 2007, 153.
14. 14 Dethlefsen, L., McFall-Ngai, M., Relman, D.A., An ecological and evolutionary perspective on human–microbe mutualism and disease. Nature 449 (2007), 811–818.
15. 15 Flint, H.J., Duncan, S.H., Scott, K.P., Louis, P., Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 9 (2007), 1101–1111.
16. 16 Hooper, L.V., Gordon, J.I., Commensal host-bacterial relationships in the gut. Science 292 (2001), 1115–1118.
17. 17 Hooper, L.V., Wong, M.H., Thelin, A., Hansson, L., Falk, P.G., Gordon, J.I., Molecular analysis of commensal host-microbial relationships in the intestine. Science 291 (2001), 881–884.
18. 18 Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
19. 19 Meylan, E., Tschopp, J., Karin, M., Intracellular pattern recognition receptors in the host response. Nature 442 (2006), 39–44.
20. 20 Frank, D.N., Zhu, W., Sartor, R.B., Li, E., Investigating the biological and clinical significance of human dysbiosis. Trends Microbiol 19 (2011), 427–434.
21. 21 Corr, S.C., Li, Y., Riedel, C.U., O'Toole, P.W., Hill, C., Gahan, C.G.M., Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci 104 (2007), 7617–7621.
22. 22 Kaper, J.B., Sperandio, V., Bacterial cell-to-cell signaling in the gastrointestinal tract. Infect Immun 73 (2005), 3197–3209.
23. 23 Stecher, B., Hardt, W.-D., The role of microbiota in infectious disease. Trends Microbiol 16 (2008), 107–114.
24. 24 Vollaard, E.J., Clasener, H.A., Colonization resistance. Antimicrob Agents Chemother 38 (1994), 409–414.
25. 25 Turnbaugh, P.J., Hamady, M., Yatsunenko, T., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
26. 26 Murphy, E.F., Cotter, P.D., Hogan, A., et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 62 (2013), 220–226.
27. 27 Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916.e7.
28. 28 Larsen, N., Vogensen, F.K., van den Berg, F.W., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 5, 2010, e9085.
29. 29 Qin, J., Li, Y., Cai, Z., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490 (2012), 55–60.
30. 30 Wang, Z., Klipfell, E., Bennett, B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
31. 31 Boursier, J., Diehl, A.M., Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog, 11, 2015, e1004559.
32. 32 Zhu, L., Baker, S.S., Gill, C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609.
33. 33 Llopis, M., Cassard, A.M., Wrzosek, L., et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65 (2016), 830–839.
34. 34 Wiest, R., Garcia-Tsao, G., Bacterial translocation (BT) in cirrhosis. Hepatology 41 (2005), 422–433.
35. 35 Nicholson, J.K., Holmes, E., Kinross, J., et al. Host-gut microbiota metabolic interactions. Science 336 (2012), 1262–1267.
36. 36 Clements, W.D., Parks, R., Erwin, P., Halliday, M.I., Barr, J., Rowlands, B.J., Role of the gut in the pathophysiology of extrahepatic biliary obstruction. Gut 39 (1996), 587–593.
37. 37 Mm, S., Km, S., Rd, S., Ea, D., Absence of intestinal bile promotes bacterial translocation. Am Surg 58 (1992), 305–310.
38. 38 Garcia-Tsao, G., Lee, F.-Y., Barden, G.E., Cartun, R., Brian West, A., Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108 (1995), 1835–1841.
39. 39 Marteau, P., Pochart, P., Doré, J., Béra-Maillet, C., Bernalier, A., Corthier, G., Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 67 (2001), 4939–4942.
40. 40 Rimola, A., Bory, F., Teres, J., Perez-Ayuso, R.M., Arroyo, V., Rodes, J., Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 5 (1985), 463–467.
41. 41 Grangie, J.-D., Roulot, D., Pelletier, G., et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 29 (1998), 430–436.
42. 42 Ginés, P., Rimola, A., Planas, R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12 (1990), 716–724.
43. 43 Gans, J., Wolinsky, M., Dunbar, J., Computational improvements reveal great bacterial diversity and high metal toxicity in soil. Science 309 (2005), 1387–1390.
44. 44 Nelson, T.A., Holmes, S., Alekseyenko, A.V., et al. PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. Neurogastroenterol Motil 23 (2011), 169–177.
45. 45 Bent, S.J., Pierson, J.D., Forney, L.J., Measuring species richness based on microbial community fingerprints: the emperor has no clothes. Appl Environ Microbiol 73 (2007), 2399–2401.
46. 46 Haas, B.J., Gevers, D., Earl, A.M., et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 21 (2011), 494–504.
47. 47 Lozupone, C., Lladser, M.E., Knights, D., Stombaugh, J., Knight, R., UniFrac: an effective distance metric for microbial community comparison. ISME J Multidiscip J Microb Ecol 5 (2011), 169–172.
48. 48 Caporaso, J.G., Kuczynski, J., Stombaugh, J., et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7 (2010), 335–336.
49. 49 Schloss, P.D., Westcott, S.L., Ryabin, T., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75 (2009), 7537–7541.
50. 50 Dumas, M.-E., Barton, R.H., Toye, A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci 103 (2006), 12511–12516.
51. 51 Langille, M.G.I., Zaneveld, J., Caporaso, J.G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 31 (2013), 814–821.
52. 52 Bajaj, J.S., Cox, I.J., Betrapally, N.S., et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 307 (2014), G951–G957.
53. 53 Bajaj, J.S., Betrapally, N.S., Hylemon, P.B., et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62 (2015), 1260–1271.
54. 54 Marchesini, G., Brizi, M., Bianchi, G., et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
55. 55 Younossi, Z.M., Stepanova, M., Afendy, M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9 (2011), 524–530.e1.
56. 56 Ong, J.P., Younossi, Z.M., Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 11 (2007), 1–16.
57. 57 Zeng, H., Liu, J., Jackson, M.I., Zhao, F.-Q., Yan, L., Combs, G.F., Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. J Nutr 143 (2013), 627–631.
58. 58 Roy, T.L., Llopis, M., Lepage, P., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62 (2013), 1787–1794.
59. 59 Henao-Mejia, J., Elinav, E., Jin, C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
60. 60 Okubo, H., Kushiyama, A., Sakoda, H., et al. Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice. Sci Rep, 6, 2016, 20157.
61. 61 Okubo, H., Sakoda, H., Kushiyama, A., et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol 305 (2013), G911–G918.
62. 62 Matsushita, N., Osaka, T., Haruta, I., et al. Effect of lipopolysaccharide on the progression of non-alcoholic fatty liver disease in high caloric diet-fed mice. Scand J Immunol 83 (2016), 109–118.
63. 63 Spencer, M.D., Hamp, T.J., Reid, R.W., Fischer, L.M., Zeisel, S.H., Fodor, A.A., Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (2011), 976–986.
64. 64 Michail, S., Lin, M., Frey, M.R., et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 91 (2015), 1–9.
65. 65 Boursier, J., Mueller, O., Barret, M., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
66. 66 Wong, V.W.-S., Tse, C.-H., Lam, T.T.-Y., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One, 8, 2013, e62885.
67. 67 Mouzaki, M., Comelli, E.M., Arendt, B.M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58 (2013), 120–127.
68. 68 Raman, M., Ahmed, I., Gillevet, P.M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11 (2013), 868–875.e3.
69. 69 Del Chierico, F., Nobili, V., Vernocchi, P., et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology, 2016 http://dx.doi.org/10.1002/hep.28572 [Epub ahead of print].
70. 70 Schnabl, B., Brenner, D.A., Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146 (2014), 1513–1524.
71. 71 Szabo, G., Bala, S., Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 16 (2010), 1321–1329.
72. 72 Parlesak, A., Schäfer, C., Schütz, T., Bode, J.C., Bode, C., Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 32 (2000), 742–747.
73. 73 Bajaj, J.S., Heuman, D.M., Hylemon, P.B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60 (2014), 940–947.
74. 74 Chen, P., Torralba, M., Tan, J., et al. Supplementation of saturated long-chain fatty acids maintains entestinal Eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148 (2015), 203–214.e16.
75. 75 Hartmann, P., Chen, P., Wang, H.J., et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 58 (2013), 108–119.
76. 76 Devkota, S., Wang, Y., Musch, M.W., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 487 (2012), 104–108.
77. 77 Tuovinen, E., Keto, J., Nikkilä, J., Mättö, J., Lähteenmäki, K., Cytokine response of human mononuclear cells induced by intestinal clostridium species. Anaerobe 19 (2013), 70–76.
78. 78 Kirpich, I.A., Petrosino, J., Ajami, N., et al. Saturated and unsaturated dietary fats differentially modulate ethanol-induced changes in gut microbiome and metabolome in a mouse model of alcoholic liver disease. Am J Pathol 186 (2016), 765–776.
79. 79 Leclercq, S., Matamoros, S., Cani, P.D., et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci 111 (2014), E4485–E4493.
80. 80 Mutlu, E.A., Gillevet, P.M., Rangwala, H., et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 302 (2012), G966–G978.
81. 81 de Timary, P., Leclercq, S., Stärkel, P., Delzenne, N., A dysbiotic subpopulation of alcohol-dependent subjects. Gut Microbes 6 (2015), 388–391.
82. 82 Merli, M., Lucidi, C., Giannelli, V., et al. Cirrhotic patients are at risk for health care–associated bacterial infections. Clin Gastroenterol Hepatol 8 (2010), 979–985.e1.
83. 83 Quigley, E.M.M., Stanton, C., Murphy, E.F., The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 58 (2013), 1020–1027.
84. 84 Wiest, R., Krag, A., Gerbes, A., Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 61 (2012), 297–310.
85. 85 Arvaniti, V., D'Amico, G., Fede, G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139 (2010), 1246–1256.e5.
86. 86 Bajaj, J.S., O'Leary, J.G., Reddy, K.R., et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 56 (2012), 2328–2335.
87. 87 Moreau, R., Jalan, R., Gines, P., et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144 (2013), 1426–1437.e9.
88. 88 Christou, L., Pappas, G., Falagas, M.E., Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 102 (2007), 1510–1517.
89. 89 Fierer, J., Finley, F., Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. J Clin Invest 63 (1979), 912–921.
90. 90 Hassner, A., Kletter, Y., Shlag, D., Yedvab, M., Aronson, M., Shibolet, S., Impaired monocyte function in liver cirrhosis. Br Med J Clin Res Ed 282 (1981), 1262–1263.
91. 91 Akalin, H.E., Laleli, Y., Telatar, H., Serum bactericidal and opsonic activities in patients with non-alcoholic cirrhosis. QJM 56 (1985), 431–437.
92. 92 Garcia-Tsao, G., Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 42 (2005), S85–S92.
93. 93 Battista, S., Bar, F., Mengozzi, G., Zanon, E., Grosso, M., Molino, G., Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 26 (1997), 75–80.
94. 94 Lumsden, A.B., Henderson, J.M., Kutner, M.H., Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8 (1988), 232–236.
95. 95 Such, J., Runyon, B.A., Spontaneous bacterial peritonitis. Clin Infect Dis Off Publ Infect Dis Soc Am 27 (1998), 669–674 quiz 675–6.
96. 96 Caly, W.R., Strauss, E., A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18 (1993), 353–358.
97. 97 Yoshida, H., Hamada, T., Inuzuka, S., Ueno, T., Sata, M., Tanikawa, K., Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 88 (1993), 2067–2071.
98. 98 Guarner, C., Soriano, G., Tomas, A., et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 18 (1993), 1139–1143.
99. 99 Francés, R., Chiva, M., Sánchez, E., et al. Bacterial translocation is downregulated by anti-TNF-α monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol 46 (2007), 797–803.
100. 100 Navasa, M., Follo, A., Filella, X., et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27 (1998), 1227–1232.
101. 101 Such, J., Hillebrand, D.J., Guarner, C., et al. Tumor necrosis factor-α, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infection. Dig Dis Sci 46 (2001), 2360–2366.
102. 102 Bajaj, J.S., Wade, J.B., Sanyal, A.J., Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 50 (2009), 2014–2021.
103. 103 Bajaj, J.S., Ridlon, J.M., Hylemon, P.B., et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 302 (2012), G168–G175.
104. 104 Bajaj, J.S., Hylemon, P.B., Ridlon, J.M., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303 (2012), G675–G685.
105. 105 Liu, Q., Duan, Z.P., Ha, D.K., Bengmark, S., Kurtovic, J., Riordan, S.M., Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39 (2004), 1441–1449.
106. 106 Zhang, Z., Zhai, H., Geng, J., et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol 108 (2013), 1601–1611.
107. 107 Obata, T., Goto, Y., Kunisawa, J., et al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci 107 (2010), 7419–7424.
108. 108 Bajaj, J.S., Betrapally, N.S., Hylemon, P.B., et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep, 5, 2015, 18559.
109. 109 Cano, P.G., Santacruz, A., Trejo, F.M., Sanz, Y., Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. Obesity 21 (2013), 2310–2321.
110. 110 Guarner, C., Runyon, B.A., Young, S., Heck, M., Sheikh, M.Y., Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 26 (1997), 1372–1378.
111. 111 Bauer, T.M., Steinbrückner, B., Brinkmann, F.E., et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 96 (2001), 2962–2967.
112. 112 Pande, C., Kumar, A., Sarin, S.K., Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 29 (2009), 1273–1281.
113. 113 Bass, N.M., Mullen, K.D., Sanyal, A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362 (2010), 1071–1081.
114. 114 Koo, H.L., DuPont, H.L., Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 26 (2010), 17–25.
115. 115 Bajaj, J.S., Heuman, D.M., Sanyal, A.J., et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One, 8, 2013, e60042.
116. 116 DuPont, H.L., Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother 12 (2011), 293–302.
117. 117 Mullen, K.D., Sanyal, A.J., Bass, N.M., et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 12 (2014), 1390–1397.e2.
118. 118 Vlachogiannakos, J., Viazis, N., Vasianopoulou, P., Vafiadis, I., Karamanolis, D.G., Ladas, S.D., Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28 (2013), 450–455.
119. 119 Bajaj, J.S., Gillevet, P.M., Patel, N.R., et al. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis 27 (2012), 205–215.
120. 120 Rayes, N., Seehofer, D., Hansen, S., et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 74 (2002), 123–127.
121. 121 Bajaj, J.S., Heuman, D.M., Hylemon, P.B., et al. Randomized clinical trial: lactobacillus gg modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39 (2014), 1113–1125.
122. 122 Adawi, D., Ahrné, S., Molin, G., Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol 70 (2001), 213–220.
123. 123 Chiva, M., Soriano, G., Rochat, I., et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37 (2002), 456–462.
124. 124 Sánchez, E., Nieto, J.C., Boullosa, A., et al. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int 35 (2015), 735–745.
125. 125 Freestone, P.P.E., Haigh, R.D., Williams, P.H., Lyte, M., Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. FEMS Microbiol Lett 172 (1999), 53–60.
126. 126 Lyte, M., Ernst, S., Catecholamine induced growth of gram negative bacteria. Life Sci 50 (1992), 203–212.
127. 127 Pérez-Paramo, M., Muñoz, J., Albillos, A., et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31 (2000), 43–48.
128. 128 Reiberger, T., Ferlitsch, A., Payer, B.A., et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 58 (2013), 911–921.
129. 129 Verbeke, L., Farre, R., Verbinnen, B., et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 185 (2015), 409–419.
130. 130 Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet 385 (2015), 956–965.
131. 131 Gao, W., Li, H.-Y., Wang, L.-X., et al. Protective effect of omeprazole on gastric mucosal of cirrhotic portal hypertension rats. Asian Pac J Trop Med 7 (2014), 402–406.